title: Peripheral T-cell lymphoma: clinicopathologic analyses of 25 cases.
abstract: Twenty-five patients with peripheral T-cell lymphoma (PTCL) were analyzed to assess clinicopathologic features of the disease and were classified according to the newly proposed histologic classification for T-cell lymphomas to study the correlation between histology and survival, if any. Histologic diagnoses were: Lennert's, 1; T-zone, 1; pleomorphic, small, 1; pleomorphic, large, 1; angiocentric, 4; pleomorphic, medium, 5; immunoblastic, 5; angioimmunoblastic, 7. Patients with PTCL were noted to be endowed with clinicopathologic factors known to adversely affect survival, such as advanced stage (92%), B symptoms (56%), liver involvement (56%), multinodal disease (52%), elevated serum LDH (48%), and so on. Response to therapy was poor. CR was obtained in 30% of patients with advanced disease with a 50% relapse rate. Median survival for the 25 patients was 13 months. No correlation was found between morphologic subtypes and survival.
authors.affiliation: Department of Medicine, Fujita Gakuen Health University School of Medicine, Aichi, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: T
authors.initials: T
authors.lastname: Nagasaka
authors.forename: K
authors.initials: K
authors.lastname: Hara
authors.forename: K
authors.initials: K
authors.lastname: Ohnishi
authors.forename: M
authors.initials: M
authors.lastname: Hirano
authors.forename: A
authors.initials: A
authors.lastname: Kunii
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology*; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D013601:T-Lymphocytes / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone